32 results about "Atrophic mucosa" patented technology

This invention discloses a pharmaceutical composition and its preparation method for treating atrophic gastritis, precancerous lesions of the stomach, and stomach cancer, belonging to the field of traditional Chinese medicine preparation technology. The pharmaceutical composition is prepared by a specific two-step microbial fermentation process using Astragalus membranaceus, Hericium erinaceus, Curcuma zedoaria, Actinidia chinensis root, Camptotheca acuminata fruit, Hedyotis diffusa, Coptis chinensis, Taraxacum mongolicum, Viola yedoensis, Corydalis yanhusuo (processed with vinegar), Phellodendron chinense, Solanum nigrum, Scutellaria baicalensis, Panax notoginseng, Zingiber officinale, Piper cubeba, Cuttlebone, Fritillaria thunbergii, roasted soybean, and red yeast rice. This invention significantly improves the bioavailability of the active pharmaceutical ingredients through the synergistic effect of the multifunctional groups of traditional Chinese medicine and the enhanced effect of microbial fermentation. It can systematically reverse gastric mucosal atrophy and intestinal metaplasia, effectively improve microcirculation, and inhibit Helicobacter pylori, while also exhibiting good safety. This provides a novel and effective treatment for the aforementioned gastric diseases.

The invention discloses a new application of Renqingchangjue and an extract of Renqingchangjue. Specifically, the invention provides a new application of Tibetan medicine Renqingchangjue and an extract in preparation of a medicine for treating chronic atrophic gastritis, and systematically clarifies an exact molecular mechanism of the Tibetan medicine Renqingchangjue for treating CAG. The core of the invention is to reveal the core signal axis of Renqingchangjue by inhibiting TNF / NF-kB / Caspase-3 for the first time, so that the Renqingchangjue synergistically exerts the effects of resisting inflammation, resisting apoptosis and promoting mucosa repair, and provides a new intervention target and scientific basis for reversing gastric mucosa gland atrophy. The invention not only provides a modern pharmacological basis for the clinical curative effect of the Renqingchangjue, but also provides a brand new technical scheme and a protection basis for developing a medicine or a medicine composition which is based on the clear pathway target and is used for treating the chronic atrophic gastritis.

The invention belongs to the technical field of traditional Chinese medicine, and particularly relates to a traditional Chinese medicine composition with the function of relieving stomach inflammation and a preparation method and application. The traditional Chinese medicine composition comprises a main medicine and an auxiliary medicine, the main medicine consists of cuttle bone, thunberg fritillary bulb and rheum officinale; the adjuvants comprise a first adjuvant and a second adjuvant; the first adjuvant is belladonna and daphniphyllum calycinum; the second adjuvant comprises fructus aurantii and cortex magnoliae officinalis. The traditional Chinese medicine composition provided by the invention is simple in component, only a trace amount of belladonna extract needs to be added, meanwhile, daphniphyllum calycinum is compounded, the addition of excessive other unnecessary components is avoided, and the symptom of chronic non-atrophic gastritis with erosion can be remarkably improved.

The invention provides a traditional Chinese medicine composition for treating chronic atrophic gastritis and a preparation method thereof. The traditional Chinese medicine composition comprises the following raw material medicines in parts by weight: 280-320 parts of red ginseng; the traditional Chinese medicine composition is prepared from the following raw materials in parts by weight: 580 to 620 parts of rhizoma atractylodis macrocephalae, 280 to 320 parts of rhizoma zingiberis, 80 to 120 parts of sandalwood, 280 to 320 parts of edible tulip, 580 to 620 parts of concha arcae, 580 to 620 parts of oldenlandia diffusa, 180 to 220 parts of notholirion bulbuliferum and 280 to 320 parts of sea buckthron oil. The total effective rate of the traditional Chinese medicine composition for treating chronic atrophic gastritis with intestinal metaplasia is 93%, and the traditional Chinese medicine composition has a remarkable clinical effect on treating chronic atrophic gastritis with intestinal metaplasia clinically.

This application proposes a traditional Chinese medicine composition and preparation method for treating atrophic gastritis of spleen deficiency and blood stasis type, involving the field of traditional Chinese medicine. It utilizes Bupleurum chinense, stir-fried Paeonia lactiflora, Citrus reticulata peel, Pinellia ternata, Codonopsis pilosula, Poria cocos, stir-fried Atractylodes macrocephala, prepared Glycyrrhiza uralensis, Agrimonia pilosa, and Curcuma zedoaria, and establishes a water extraction and decoction preparation process. A rat model of precancerous gastric lesions was established using MNNG combined with multiple factors. Normal control group, model group, folic acid group, and traditional Chinese medicine group were set up to observe the morphological and pathological changes of the gastric mucosa. The results showed that the traditional Chinese medicine composition can reduce gastric mucosal atrophy, inflammatory cell infiltration, and fibrous tissue hyperplasia, alleviate intestinal metaplasia, downregulate the expression of AKT and mTOR proteins in the gastric mucosa, and inhibit abnormal mucosal proliferation. Its effect is superior to that of folic acid, providing experimental evidence for clinical treatment.

This invention provides a traditional Chinese medicine composition for treating chronic atrophic gastritis and its application, belonging to the field of traditional Chinese medicine technology. The traditional Chinese medicine composition for treating chronic atrophic gastritis provided by this invention is made from the following raw materials in parts by weight: 15-25 parts of Salvia miltiorrhiza, 8-16 parts of Curcuma zedoaria (processed with vinegar), 2-6 parts of Eupolyphaga sinensis, 10-20 parts of Codonopsis pilosula, 8-16 parts of Dendrobium nobile (dried), 5-15 parts of Pinellia ternata (processed), 1-5 parts of Evodia rutaecarpa (processed), and 1-5 parts of Coptis chinensis. It has the effects of promoting blood circulation and removing blood stasis, strengthening the spleen and replenishing qi, nourishing yin and benefiting the stomach, inhibiting bacteria and inflammation, and regulating immunity. It is suitable for chronic atrophic gastritis, especially those with gastric blood stasis combined with stomach yin deficiency or spleen and stomach weakness. It can significantly repair the gastric mucosa and reverse atrophic intestinal metaplasia, and is safe and reliable, providing a new traditional Chinese medicine treatment for chronic atrophic gastritis.

The invention discloses a traditional Chinese medicine formula for treating atrophic gastritis with intestinal metaplasia and atypical hyperplasia and a preparation method thereof, and belongs to the technical field of traditional Chinese medicine formulas. The traditional Chinese medicine composition comprises the following components in parts by weight: 16-20 parts of Zhejiang radix ophiopogonis, 15-20 parts of moutan bark, 28-32 parts of salvia miltiorrhiza, 10-14 parts of pseudo-ginseng slices, 15-18 parts of curcuma zedoary, 18-22 parts of codonopsis pilosula, 28-32 parts of astragalus membranaceus and 28-32 parts of oldenlandia diffusa. The preparation method comprises the following steps: (1) cleaning the medicinal materials, and then cutting into small blocks to obtain a mixed medicinal material; (3) boiling with big fire after soaking, continuing to decoct with small fire, and filtering to obtain first medicine liquid and medicine residues; and (4) adding water again, boiling with big fire, continuously decocting with small fire, filtering to obtain a second liquid medicine, and mixing the first liquid medicine and the second liquid medicine. The traditional Chinese medicine composition can obviously improve inflammation and atrophic lesion of gastric mucosa, and has a remarkable effect on treating atrophic gastritis with intestinal metaplasia and atypical hyperplasia.

The present application belongs to the technical field of bioinformatics, and specifically relates to a chronic atrophic gastritis biomarker screening method and system based on a multi-modal differential network. The present application comprises: preprocessing metabolome data and microbiome data, respectively constructing intra-modal interaction graphs and inter-modal interaction graphs, and obtaining a multi-modal differential network by making a difference between the interaction graphs under different clinical groupings; based on the constructed differential network, a multi-level difference evaluation index is constructed: CDI is calculated at the node level to quantify the network topology and biological function differences of the biomarkers; at the structure level, a group specificity index GSI is defined to characterize the group specificity of the differential network structure; the feature ranking results obtained by CDI and GSI are fused and screened to obtain a biomarker set for atrophic gastritis classification prediction. The present application improves the effectiveness of biomarker screening under the condition of small sample and high dimension, and provides support for subsequent targeted cultivation of candidate colonies and metabolites and development of potential intervention target points.

The invention relates to the technical field of medicines, in particular to a traditional Chinese medicine composition for treating chronic atrophic gastritis and a preparation method thereof. Comprising the following raw materials in parts by weight: 25-35 parts of honey-fried astragalus membranaceus, 10-15 parts of roasted rhizoma atractylodis macrocephalae, 8-10 parts of ginseng, 5-8 parts of elecampane, 2-4 parts of fructus amomi, 12-18 parts of codonopsis pilosula, 12-18 parts of poria cocos, 8-10 parts of vinegar-processed curcuma zedoary, 2-4 parts of pseudo-ginseng, 8-12 parts of oldenlandia diffusa, 10-15 parts of medlar, 8-10 parts of pericarpium citri reticulatae, 5-7 parts of ginger processed pinellia, 0.08-0.12 part of naringin and 5-7 parts of liquorice. The traditional Chinese medicine composition disclosed by the invention takes spleen invigorating and qi supplementing, qi regulating and blood activating, precise regulation and control and mucous membrane repairing as the core, specifically solves the pathogenesis of spleen deficiency and qi stagnation type CAG with deficiency in root and excess in excess, inhibits the progression of precancerous lesions, and improves the treatment effectiveness and safety.

This invention belongs to the field of gastric disease treatment, specifically relating to a traditional Chinese medicine composition for treating chronic atrophic gastritis with intestinal metaplasia and its preparation method. The traditional Chinese medicine composition for treating chronic atrophic gastritis with intestinal metaplasia comprises the following raw materials in parts by weight: Agrimonia pilosa 10-15 parts, Cyperus rotundus 8-10 parts, Scutellaria barbata 10-15 parts, Lobelia chinensis 10-15 parts, Patrinia scabiosaefolia 13-17 parts, Scutellaria baicalensis 7-11 parts, Hedyotis diffusa 10-15 parts, Prunella vulgaris 10-15 parts, Hedyotis diffusa 5-7 parts, Perilla frutescens 8-10 parts, Coptis chinensis 5-7 parts, Angelica sinensis 5-7 parts, etc. This invention focuses on the core pathogenesis of damp-heat in the spleen and stomach and stagnation of gastric collaterals. The Chinese herbal composition has the effects of clearing heat and removing dampness, regulating qi and harmonizing the stomach, nourishing blood and unblocking collaterals. Clinically, it can significantly improve the OLGA / OLGIM stage of patients with chronic atrophic gastritis with intestinal metaplasia, with a total effective rate of 65.1%, providing a safe and effective Chinese medicine solution for precancerous lesions of the stomach.

The invention belongs to the technical field of medicines, and particularly relates to application of hibiscus (the hibiscus is a plant hibiscus flower and an extract and an active monomer thereof) in preparation of medicines for treating stomach diseases (atrophic gastritis, gastric mucosal lesion and gastric cancer). The invention discloses application of hibiscus syriacus in treatment of gastric diseases. The application comprises at least one of chronic atrophic gastritis treatment, gastric mucosa protection and gastric cancer prevention. In-vitro experiments show that the shrub althea flower extract, shrub althea flower polyphenol, syringic acid (I), protocatechuic acid (II), kaempferol (III) and kaempferol-7-O-beta-D-glucoside (IV) have obvious antioxidant activity and gastric mucosa protection activity, can obviously reduce the ROS content in ethanol-induced GES-1 cells and the expression of apoptosis marker protein Caspase-3 / Bax, and have a wide application prospect.

This invention discloses a traditional Chinese medicine drug for treating atrophic gastritis and its preparation method. The drug is composed of herbs including Salvia miltiorrhiza, chicken gizzard lining, Aucklandia lappa, Amomum villosum, Taraxacum mongolicum, Shenqu (medicated leaven), Citrus aurantium, Corydalis yanhusuo, Coix lacryma-jobi, Viola yedoensis, Angelica sinensis, and Astragalus membranaceus. In preparation, about half of the herbal mixture is pulverized into a fine powder for later use; the remaining herbs are decocted twice with water, and the filtrate is concentrated into a thick paste using vacuum low-temperature concentration technology. The thick paste is mixed with the fine herbal powder, ethanol is added, and wet microcapsules are prepared using an extrusion and spheronization method. The wet microcapsules are finally dried in stages using a fluidized bed and polished to obtain the finished product. This method, by combining extraction with the use of raw powder, and employing key processes such as low-temperature concentration and staged drying, can maximize the retention of water-soluble and heat-sensitive volatile components in the herbs, significantly improving the drug's dissolution rate, active ingredient content, and long-term storage stability, thereby more effectively exerting its comprehensive therapeutic effects of invigorating the spleen and replenishing qi, promoting blood circulation and removing blood stasis, and relieving pain.

The invention specifically discloses a nine-ingredient bacon formula for treating chronic atrophic gastritis as well as a preparation method and application thereof, and relates to the technical field of biological medicines. The nine-ingredient Bayuan prescription provided by the invention is designed for the core pathogenesis of spleen and stomach weakness and qi and blood disharmony of CAG, and has the effects of strengthening the spleen and stomach, consolidating the root and Bayuan, and regulating qi to alleviate pain.

The invention discloses a traditional Chinese medicine composition for treating atrophic gastritis precancerous lesions and a preparation method thereof. The traditional Chinese medicine composition is prepared from the following raw material medicines: radix astragali, fructus mume, cortex cinnamomi, rhizoma curcumae, raw endothelium corneum gigeriae galli, rhizoma coptidis and radix glycyrrhizae preparata. The traditional Chinese medicine composition is remarkable in curative effect, has advantages in the aspects of gastric mucosa pathology improvement, endoscopic scoring, clinical symptoms and syndromes compared with a Chinese patent medicine Weifuchun capsule which is commonly used for treating atrophic gastritis precancerous lesions clinically, does not have obvious adverse reaction, and is good in safety.

The present application provides the application of Rabdosia serra extract in the preparation of drugs for treating atrophic gastritis and precancerous lesions of gastric cancer, wherein the Rabdosia serra extract includes Rabdosia serra aerial part extract, Rabdosia serra underground part extract, Rabdosia serra total part extract and eluate thereof, etc. The present application also provides the application of compounds in Rabdosia serra in the preparation of drugs for treating atrophic gastritis and precancerous lesions of gastric cancer, wherein the compounds in Rabdosia serra are selected from oridonin, rabdosin C, norcantharidin, raxofelone and rabdosiin A. The present application proves that Rabdosia serra extract and the compounds in Rabdosia serra have good activity of reversing precancerous lesions of gastric cancer by constructing a cell model (MC cell model) of atrophic gastritis and precancerous lesions of gastric cancer by stimulating GES-1 cells with MNNG.

The invention discloses a traditional Chinese medicine composition for treating atrophic gastritis and a preparation method of the traditional Chinese medicine composition for treating atrophic gastritis. The traditional Chinese medicine composition is prepared from the following raw materials in parts by weight: 3-10 parts of angelica sinensis, 3-10 parts of ligusticum wallichii, 10-30 parts of radix paeoniae alba, 5-20 parts of dandelion, 10-30 parts of herba ecliptae, 5-20 parts of sculellaria barbata, 5-20 parts of semen litchi, 5-20 parts of fructus aurantii, 10-30 parts of lily, 5-20 parts of mangnolia officinalis, 5-20 parts of radices trichosanthis, 10-30 parts of oriental wormwood, 3-10 parts of endothelium corneum gigeriae galli, 10-30 parts of oldenlandia diffusa, 10-30 parts of honeysuckle and 2-10 parts of liquorice. The traditional Chinese medicine composition can well treat atrophic gastritis, and is remarkable in effect, safe and reliable.

The invention discloses a method for segmenting a focus area in an atrophic gastritis endoscopic image, and mainly relates to the technical field of medical image segmentation. Comprising the following steps: S1, collecting an atrophic gastritis endoscopic image to obtain an atrophic gastritis endoscopic image data set; s2, constructing a structure sensing context enhancement and double-channel collaborative decoding network; s3, constructing a structure perception composite loss function; s4, performing model training to obtain a structure perception context enhancement and double-path collaborative decoding model; s5, inputting the atrophic gastritis endoscopic image into the structure perception context enhancement and double-path collaborative decoding model to complete segmentation of a focus area in the atrophic gastritis endoscopic image; the method can effectively solve the problems of low segmentation precision and poor robustness under the background of fuzzy lesion boundary, low contrast, complex structural form and multi-source interference in the prior art, thereby providing reliable technical support for auxiliary screening, targeted biopsy and lesion progress monitoring of early gastric cancer under an endoscope.

The application discloses a traditional Chinese medicine composition for treating chronic atrophic gastritis with low-grade intra-epithelial neoplasia and a preparation method and application thereof. The traditional Chinese medicine composition is prepared from raw materials including radix astragali 10-15 parts, rhizoma atractylodis macrocephalae 8-10 parts, poria cocos 10-15 parts, pericarpium citri reticulatae 8-10 parts, rhizoma pinelliae 5-8 parts, cyperus rotundus 12-15 parts, panax notoginseng 3-5 parts, radix curcumae 10-12 parts, root of actinidia 15-20 parts, herba hedyotis diffusae 15-20 parts and herba scorpiuridis 10-15 parts. The traditional Chinese medicine composition has good effects of improving gastric mucosa atrophy and low-grade intra-epithelial neoplasia, and has important application prospects for development of drugs for simple chronic atrophic gastritis and chronic atrophic gastritis combined with low-grade intra-epithelial neoplasia.

The invention belongs to the technical field of medical experimental animal models, and particularly relates to a construction method of a spleen and stomach damp-heat syndrome chronic atrophic gastritis animal model. The construction method comprises the following steps: firstly, performing spleen and stomach damp-heat modeling on a tested animal to obtain spleen and stomach damp-heat syndromes, and then performing chronic atrophic gastritis induction. According to the specific three-step atrophic gastritis induction method, the clinical pathological process of inflammation caused by stimulation, gastric mucosa atrophy caused by damp heat and blood stasis for a long time and intestinal metaplasia can be accurately copied, the clinical pathological process is highly matched with the stage progress characteristic of clinical chronic atrophic gastritis, and the model is high in success rate, good in stability and high in repeatability.

This invention provides a gastric mucosal IM-SPEM organoid model, its construction method, and its applications, belonging to the field of biological technology. The construction method includes: polarizing mouse bone marrow-derived macrophages, and co-culturing the polarized macrophages with mouse gastric organoids. The gastric mucosal IM-SPEM organoid model constructed by this method can highly simulate the key pathological process of gastric "inflammation-cancer" transformation driven by a chronic inflammatory microenvironment in the human gastric mucosa, accurately reproducing the development path of normal gastric mucosa transforming from chronic non-atrophic gastritis to atrophic gastritis, SPEM, and IM lesions. This model integrates a multi-dimensional regulatory network including immune signaling, epithelial cell damage response, and stem cell fate reprogramming, and can dynamically monitor the interaction mechanism between macrophages and gastric epithelial cells, overcoming the technical deficiencies of traditional IM cell models in simulating complex in vivo microenvironments and analyzing intercellular communication mechanisms.

The invention provides a novel ferroptosis inhibitor as well as a preparation method and application thereof, and belongs to the technical field of chemical synthesis medicines. The invention synthesizes a compound shown in the formula I and having a good inhibition effect on ferroptosis, and the compound can be used for preparing a ferroptosis inhibitor. The compound can also be used for preparing medicines for treating diseases such as ischemia-reperfusion injury, drug-induced liver injury, acute kidney injury, renal failure, hepatic pulmonary fibrosis, neurodegenerative diseases, cerebral apoplexy, myocarditis, myocardial infarction, heart failure, arthritis, chronic atrophic gastritis and the like related to ferroptosis, and has a wide market prospect.

The invention discloses a marker screening method, medium and equipment for distinguishing atrophic gastritis damp-heat syndrome, and the method comprises the following steps: obtaining a testee tongue coating sample, carrying out microbiomics and non-targeted metabonomics analysis on the testee tongue coating sample, and respectively obtaining tongue coating flora marker data and tongue coating metabolite marker data; and fusing the two types of data to construct a fusion feature vector, and inputting the fusion feature vector into a trained prediction model to output a risk level or a classification result for indicating that the subject suffers from the chronic atrophic gastritis damp-heat syndrome. According to the method, through deep fusion of multiple omics data, complex interaction between microorganisms and metabolites is effectively captured, and the accuracy and reliability of distinguishing and screening the damp-heat syndrome of the atrophic gastritis are remarkably improved.

According to the chronic atrophic gastritis clinical prediction model based on the random forest algorithm, the SHAP method is used for explaining and illustrating feature importance and explaining the prediction result of the model so as to determine relevant risk factors of the CAG, and reliable clinical evidence is provided for screening high-risk groups before endoscopic examination of the CAG. Meanwhile, the invention further provides a visual webpage platform based on a Shiny framework, namely a chronic atrophic gastritis clinical prediction platform based on a random forest algorithm, a doctor can visually obtain an individual CAG risk prediction value, operation is easy and convenient, practicability is high, and clinical application and popularization are facilitated.

The invention relates to the field of traditional Chinese medicines, in particular to a traditional Chinese medicine composition and a pharmaceutical preparation as well as a preparation method and application of the traditional Chinese medicine composition and the pharmaceutical preparation. In the formula, astragalus membranaceus is used as a monarch drug, poria cocos, pericarpium citri reticulatae, bran-fried fructus aurantii and ginger-processed cortex magnoliae officinalis are combined as ministerial drugs, and scutellaria baicalensis, coptis chinensis, cortex phellodendri, rhizoma pinellinae praeparata, vinegar-processed rhizoma corydalis, radix curcumae, vinegar-processed radix bupleuri, fried almond and scalded hedgehog hide are combined as adjuvant drugs; and finally, scorched hawthorn fruit, scorched medicated leaven, scorched malt and vinegar-processed endothelium corneum gigeriae galli The traditional Chinese medicines jointly have the effects of replenishing qi to invigorate the spleen, eliminating dampness, dissolving phlegm, clearing heat, removing blood stasis, dispersing stagnation and dredging collaterals, and can obviously improve the pathological symptoms of chronic mucosal inflammation, gland atrophy, intestinal metaplasia and the like of patients with chronic atrophic gastritis.

The invention discloses a stomach-invigorating and digestion-promoting herb endothelium corneum gigeriae galli composition as well as a preparation method and application thereof. The composition comprises the following components in percentage by weight: 15-25% of an endothelium corneum gigeriae galli extract, 8-15% of a cuttle bone extract, 12-22% of an amomum cardamomum extract, 10-18% of a bighead atractylodes rhizome extract, 8-16% of a radix aucklandiae extract, 5-12% of a fructus amomi extract, 5-10% of a rhizoma kaempferiae extract, 1-3% of a gastrointestinal bio-enzyme preparation and 1.0-2.0% of stevioside. According to the invention, traditional medicinal and edible medicinal materials are combined with a modern biological enzyme technology, and active components are effectively reserved by optimizing extraction process parameters, such as alkaline homogenization combined with dialysis purification of endothelium corneum gigeriae galli, ethanol reflux extraction of cuttle bone, ultrasonic-assisted extraction of amomum cardamomum and the like. The composition can be prepared into powder or drink, has multiple effects of invigorating stomach and promoting digestion, promoting qi circulation and relieving pain, relieving acid and stopping bleeding, repairing gastric mucosa and the like, and is suitable for treating various gastrointestinal diseases such as stomachache, gasteremphraxis, sour regurgitation, atrophic gastritis, gastric ulcer and the like.

The application discloses a traditional Chinese medicine composition for chronic active-atrophic gastritis and a preparation method thereof, and belongs to the technical field of traditional Chinese medicines, aiming at solving the technical problems that there is no traditional Chinese medicine composition for treating Hp infection in combination of traditional Chinese medicine and western medicine or the treatment effect is poor. The traditional Chinese medicine composition for chronic active-atrophic gastritis is prepared from the following traditional Chinese medicinal materials according to weight parts: Fructus Aurantii 10-15 parts, Rhizoma Pinelliae Praeparatum 8-12 parts, Rhizoma Atractylodis Macrocephalae 10-20 parts, Radix Pseudostellariae 20-40 parts, Pericarpium Citri Reticulatae Viride 8-12 parts, Rhizoma Coptidis 5-8 parts, Radix Paeoniae Rubra 10-20 parts, Fritillariae Thunbergii 10-20 parts, Radix Glycyrrhizae 5-8 parts, Radix Rehmanniae Preparata 20-40 parts, Fructus Evodiae 1-3 parts and Herba Taraxaci 10-20 parts. The traditional Chinese medicine composition has the advantages of good curative effect, low drug resistance, and the like, and the combination of the traditional Chinese medicine composition and a conventional anti-Helicobacter pylori scheme can obviously alleviate the clinical symptoms of patients and improve the life quality of patients.

The invention provides a traditional Chinese medicine composition for treating chronic atrophic gastritis with intestinal metaplasia, which is prepared from 16 medicinal materials, namely ginseng, vinegar turtle shell, curcuma zedoary, astragalus membranaceus, bighead atractylodes rhizome, poria cocos, radix bupleuri, white paeony root, pericarpium citri reticulatae, rhizoma pinelliae preparata, angelica sinensis, moutan bark, fructus amomi, almond, cassia twig and honey-fried licorice root, and a specific process that the vinegar turtle shell is crushed to 3-5mm and then decocted is adopted. According to the treatment principle of tonifying qi, promoting tissue regeneration, dredging collaterals, removing food retention and guiding ascending and descending, astragalus membranaceus and ginseng are matched to tonify qi and promote mucosa regeneration; vinegar turtle shell and curcuma zedoary can enter collaterals to remove blood stasis and remove food retention; the almonds and the cassia twigs are matched to form a Qi movement guide of ventilating and dredging, so that the medicine accurately acts on the gastric submucosa. Through clinical observation of 120 patients with chronic atrophic gastritis accompanied with intestinal metaplasia, the total effective rate is 96.7%, the obvious effective rate is 91.7%, the mucosa improvement rate under a gastroscope is 92.5%, the intestinal metaplasia reversal rate is 68.3%, the recurrence rate is only 3.3% after 6 months, and the occurrence rate of liver and kidney dysfunction of the patients is 0%. The contrast experiment further proves that the intestinal metaplasia reversion rate is only 42.5% after the apricot kernels and the cassia twigs are removed. The traditional Chinese medicine composition can quickly reverse atrophy and intestinal metaplasia, promote mucosa repair, protect healthy qi and reduce relapse, and overcomes the defects that a traditional blood stasis dispersing and tonifying prescription is prone to injuring healthy qi, assists dampness and heat and is low in reversion rate.

The invention discloses application of radices stellariae dichotomae polysaccharide in preparation of medicine for treating chronic non-atrophic gastritis, radices stellariae dichotomae polysaccharide gastric floating tablets and a preparation method thereof, and relates to the technical field of natural medicine preparations. System experiments prove that the radices stellariae dichotomae polysaccharide can play a role in treating chronic non-atrophic gastritis (CNAG) through triple mechanisms of regulating inflammatory response, improving oxidative stress and intervening a key signal channel for the first time; meanwhile, aiming at the problem of low gastrointestinal tract bioavailability of radices stellariae dichotomae polysaccharide, the gastric floating tablet preparation is designed and optimized, and the optimal prescription is determined by combining a wet granulation tabletting method with a Box-Behnken response surface method, so that long-acting retention and stable release of the medicine in the stomach are realized. The preparation has the advantages of high safety, strong targeting property, lasting curative effect and the like, and a novel natural medicine selection and a matched preparation technology are provided for clinical treatment of CNAG.

The application discloses a traditional Chinese medicine composition for treating precancerous lesions of atrophic gastritis and a preparation method thereof. Raw material medicines of the traditional Chinese medicine composition are as follows: Astragalus membranaceus, Fructus Mume, Cinnamomum cassia, Curcuma zedoary, raw chicken gizzard, Coptis chinensis and honey-fried licorice. The traditional Chinese medicine composition has remarkable curative effect, has advantages in improving gastric mucosa pathology, endoscopic score, clinical symptoms and syndrome compared with Weifuchun Capsules, a Chinese patent drug commonly used for treating precancerous lesions of atrophic gastritis, and has no obvious adverse reactions and good safety.

This invention discloses the application of a traditional Chinese medicine composition in the preparation of drugs for the prevention and treatment of gastritis. The composition comprises the following ingredients: Astragalus membranaceus, ginseng, Atractylodes macrocephala, fermented Cordyceps militaris powder, Lycium barbarum, Hedyotis diffusa, Fagopyrum dibotrys, Bistorta officinalis, Panax notoginseng, and Caesalpinia sappan. This invention is the first to discover and confirm that this traditional Chinese medicine composition can be used to prevent or treat chronic gastritis, especially chronic atrophic gastritis. Experiments have verified that it can significantly prevent or improve the pathological state of the gastric mucosa in rats with chronic atrophic gastritis. Specifically, it can significantly increase the serum pepsinogen I / II ratio, decrease gastrin-17 levels, reverse gastric gland atrophy, and repair the morphological structure of the gastric mucosa, achieving a systematic repair of the function and structure of the CAG gastric mucosa. Furthermore, the ingredients in this traditional Chinese medicine composition are rationally combined, and no obvious toxic side effects were observed under experimental conditions, demonstrating good safety and potential for long-term use.